Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors (original) (raw)
Khuri FR, Herbst RS, Fossella FV . Emerging therapies in non-small-cell lung cancer. Ann Oncol 2001; 12: 739–744. ArticleCASPubMed Google Scholar
Vora SA, Daly BD, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S et al. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer 2000; 89: 1946–1952. ArticleCASPubMed Google Scholar
Elankumaran S, Rockemann D, Samal SK . Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006; 80: 7522–7534. ArticleCASPubMedPubMed Central Google Scholar
Sinkovics JG, Horvath JC . Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000; 16: 1–15. ArticleCASPubMed Google Scholar
Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z . The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol 1995; 121: 169–174. ArticleCASPubMed Google Scholar
Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619–627. CASPubMed Google Scholar
Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T . Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1999; 19: 635–638. CASPubMed Google Scholar
Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221–228. ArticleCASPubMed Google Scholar
Schirrmacher V, Haas C, Bonifer R, Ertel C . Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 1997; 3: 1135–1148. CASPubMed Google Scholar
Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994; 54: 6017–6021. CASPubMed Google Scholar
Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677–696. CASPubMed Google Scholar
Schirrmacher V, Jurianz K, Roth C, Griesbach A, Bonifer R, Zawatzky R . Tumor stimulator cell modification by infection with Newcastle disease virus: analysis of effects and mechanism in MLTC-CML cultures. Int J Oncol 1999; 14: 205–215. CASPubMed Google Scholar
Lorence RM, Rood PA, Kelley KW . Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 1988; 80: 1305–1312. ArticleCASPubMed Google Scholar
Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J . Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 1994; 9: 225–235. ArticleCASPubMed Google Scholar
Krishnamurthy S, Takimoto T, Scroggs RA, Portner A . Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80: 5145–5155. ArticleCASPubMedPubMed Central Google Scholar
Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821–825. ArticleCASPubMed Google Scholar
Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275. ArticleCASPubMed Google Scholar
Vermeulen K, Van Bockstaele DR, Berneman ZN . Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627–639. ArticleCASPubMed Google Scholar
Weaver BK, Ando O, Kumar KP, Reich NC . Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB J 2001; 15: 501–515. ArticleCASPubMed Google Scholar
Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z . Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol 1996; 122: 409–415. ArticleCASPubMed Google Scholar
Cheville NF, Beard CW . Cytopathology of Newcastle disease. The influence of bursal and thymic lymphoid systems in the chicken. Lab Invest 1972; 27: 129–143. CASPubMed Google Scholar
Hitchner SB, Johnson EP . A virus of low virulence for immunizing fowls against Newcastle disease (avian pneumoencephalitis). Vet Med 1948; 43: 525–530. CASPubMed Google Scholar
Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O et al. Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 2006; 114: 731–743. ArticlePubMed Google Scholar
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 973; 51: 1417–1423. Article Google Scholar
Jacobs JP, Jones CM, Baille JP . Characteristics of a human diploid cell designated MRC-5. Nature 1970; 227: 168–170. ArticleCASPubMed Google Scholar
Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res 2005; 11: 4955–4961. ArticleCASPubMed Google Scholar
Sever JL . Application of a microtechnique to viral serological investigations. J Immunol 1962; 88: 320–329. CASPubMed Google Scholar
Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ et al. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 2005; 71: 223–229. ArticleCASPubMed Google Scholar
Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240–1242. ArticleCASPubMed Google Scholar
Pitha PM, Kunzi MS . Type I interferon: the ever unfolding story. Curr Top Microbiol Immunol 2007; 316: 41–70. CASPubMed Google Scholar
Darzynkiewicz Z, Bedner E, Smolewski P . Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 2001; 38: 179–193. ArticleCASPubMed Google Scholar
Hande KR . Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34: 1514–1521. ArticleCASPubMed Google Scholar
Matza-Porges S, Horresh I, Tavor E, Panet A, Honigman A . Expression of an anti apoptotic recombinant short peptide in mammalian cells. Apoptosis 2005; 10: 987–996. ArticleCASPubMed Google Scholar
Nagai Y . Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9: 83–99. ArticleCASPubMed Google Scholar
Castagnetta LA, Carruba G . Human prostate cancer: a direct role for oestrogens. Ciba Found Symp 1995; 191: 269–286. CASPubMed Google Scholar
Peeters BP, de Leeuw OS, Koch G, Gielkens AL . Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999; 73: 5001–5009. CASPubMedPubMed Central Google Scholar
Romer-Oberdorfer A, Werner O, Veits J, Mebatsion T, Mettenleiter TC . Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J Gen Virol 2003; 84 (Partt 11): 3121–3129. ArticlePubMed Google Scholar
Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V . Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 2006; 119: 328–338. ArticleCASPubMed Google Scholar
Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P . Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77: 9522–9532. ArticleCASPubMedPubMed Central Google Scholar
Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 2003; 77: 1501–1511. ArticleCASPubMedPubMed Central Google Scholar
Apostolidis L, Schirrmacher V, Fournier P . Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 2007; 31: 1009–1019. CASPubMed Google Scholar
Fabian Z, Csatary CM, Szeberenyi J, Csatary LK . p53-Independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007; 81: 2817–2830. ArticleCASPubMedPubMed Central Google Scholar
Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251–2266. ArticleCASPubMed Google Scholar
Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O’Neil JD et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 2007; 13: 977–985. ArticleCASPubMed Google Scholar
Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267: 13573–13579. CASPubMed Google Scholar
Stram Y, Shchori D, Chinitch Y, David D, Molad T, Samina I . Molecular characterization of an unassigned Israeli Newcastle disease virus isolate. Avian Dis 1998; 42: 746–751. ArticleCASPubMed Google Scholar
Reed LJ, Muench HA . A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493–497. Google Scholar
Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG . Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ 1973; 48: 199–202. CASPubMedPubMed Central Google Scholar
Luther P, Klett GE, Weber S, Pechmann H, Bergmann KC . The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J Biol Stand 1983; 11: 115–121. ArticleCASPubMed Google Scholar
Gotoh BYF, Ogasawara T, Nagai Y . Isolation of factor Xa from chick embryo as the amniotic endoprotease responsible for paramyxovirus activation. FEBS Lett 1992; 296: 274–278. ArticleCASPubMed Google Scholar